
After months of back and forth, the National Institute for Health and Care Excellence (NICE) has decided that Leo Pharma’s monoclonal antibody Adtralza (tralokinumab) can be recommended as a treatment for moderate to severe eczema.
In a press release, Leo Pharma reveals that this decision means Adtralza can become a standard treatment for adult patients in England and Wales who are good candidates for systemic therapies. However, patients must have tried one systemic immuno-suppressive treatment before being prescribed Adtralza.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app